Trevena's TRV130 meets in Phase II pain trial

Trevena Inc. (NASDAQ:TRVN) gained $2.48 (41%) to $8.48 in after-hours trading after TRV130 met its primary endpoint in a Phase IIb trial to treat moderate to severe acute postoperative pain after abdominoplasty surgery.

The 200 patients in the trial received one of two TRV130 regimens, morphine or placebo. The TRV130 regimens consisted of a 1.5 mg IV loading dose plus 0.1 mg or 0.35 mg on-demand doses. Patients in the morphine and placebo groups also received loading doses followed by on-demand doses. ...